Experts analyse growth in the finished dosage market
CPhI Worldwide has released the findings from its debate on the global growth in finished dosage forms, ahead of the launch of a new co-located event at CPhI Worldwide on October 4th and 6th.
The new Finished Dosage Formulation (FDF) event will be the first global pharma platform dedicated to the manufacture, development and supply of finished dosage forms.
Cara Turner, Event Manager for Finished Dosage Formulation, said: “Companies producing finished formulations need to partner and outsource more to get the correct mix of technologies and this is where we saw a huge opportunity for CPhI to introduce a finished dosage event.
What we are attempting to do is bring Big Pharma and CMOs, to out-licensing and dossier specialists, end product distributors, and generic pharma companies to one location so that our clients can find new partners.”
Alan Sheppard, Principal, Global Generics and Biosimilars at IMS Health, said: “Outsourcing for delivery systems is another key trend, as is partnering with more established companies in specific segments. For instance, if you only have a single oncology product, partnering and out-licensing with someone who has a wider dossier is a very good strategy.
One company cannot offer full development capabilities, we need outsourcing to increase knowledge, whether in terms of local market entry, manufacturing, development or distribution.”
Citing IMS figures, Sheppard reported that, in the last 4-years, the USA (58%) and Europe (17%) have dominated growth in new speciality medicines – with the largest profit opportunities in smaller patient cohorts and speciality drugs, where there are still unmet patient needs.
Although the US represents 28% of growth, the pharmerging markets are the driving force underlying this with 58% of growth.
Rutger Oudejans, Brand Director - Pharma at UBM EMEA, commeted: “We envisage this sector of CPhI Worldwide to drive considerable growth and importantly, attract a new delegate profile to the event. There are clear opportunities for diagnostic providers, licensors, delivery platforms and distributors, in addition to our current visitor base who will have access to a wider range of partners.”